Apogee Therapeutics, Inc. financial data

Symbol
APGE on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
221 Crescent St., Building 17, Suite 102 B, Waltham, Massachusetts
Fiscal year end
December 31
Former names
Apogee Therapeutics, LLC (to 6/12/2023)
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.77K %
Return On Assets -19.3 %

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 56.7M shares
Entity Public Float 0 USD
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 56.5M shares +1030%
Weighted Average Number of Shares Outstanding, Diluted 56.5M shares +1030%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 108M USD +138%
General and Administrative Expense 35.8M USD +121%
Operating Income (Loss) -144M USD -134%
Net Income (Loss) Attributable to Parent -118M USD -82.1%
Earnings Per Share, Basic 1.69 USD/shares +84.1%
Earnings Per Share, Diluted 1.69 USD/shares +84.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 307M USD +146%
Marketable Securities, Current 369M USD
Other Assets, Current 3.39M USD +282%
Assets, Current 682M USD +422%
Property, Plant and Equipment, Net 714K USD
Operating Lease, Right-of-Use Asset 4.23M USD
Other Assets, Noncurrent 468K USD
Assets 801M USD +513%
Accounts Payable, Current 5.53M USD -50.4%
Employee-related Liabilities, Current 4.06M USD +358%
Accrued Liabilities, Current 17.4M USD +169%
Liabilities, Current 24.6M USD +39.8%
Operating Lease, Liability, Noncurrent 2.4M USD
Liabilities 27M USD +53.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -289K USD
Retained Earnings (Accumulated Deficit) -190M USD -166%
Liabilities and Equity 801M USD +513%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.6M USD -200%
Net Cash Provided by (Used in) Financing Activities 451M USD
Net Cash Provided by (Used in) Investing Activities -51.7M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 58.5M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 367M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 308M USD +146%
Deferred Tax Assets, Valuation Allowance 30.2M USD +352%
Deferred Tax Assets, Gross 30.8M USD +360%
Operating Lease, Liability 4.1M USD
Depreciation 29K USD
Payments to Acquire Property, Plant, and Equipment 351K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -119M USD -79.7%
Lessee, Operating Lease, Liability, to be Paid 2.21M USD
Operating Lease, Liability, Current 1.68M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 964K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.24M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 174K USD
Deferred Tax Assets, Operating Loss Carryforwards 5.37M USD +766%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 904K USD
Additional Paid in Capital 964M USD
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 13.6M USD +412%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares